Androgen receptor

Source: Wikipedia, the free encyclopedia.
AR
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_001011645
NM_000044
NM_001348061
NM_001348063
NM_001348064

NM_013476

RefSeq (protein)

NP_038504

Location (UCSC)Chr X: 67.54 – 67.73 MbChr X: 97.19 – 97.37 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse
Androgen_recep
crystal structure of the human androgen receptor ligand binding domain bound with an androgen receptor nh2-terminal peptide, ar20-30, and r1881
Identifiers
SymbolAndrogen_recep
PfamPF02166
InterProIPR001103
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
Normal function of the androgen receptor. Testosterone (T) enters the cell and, if 5-alpha-reductase is present, is converted into dihydrotestosterone (DHT). Upon steroid binding, the androgen receptor (AR) undergoes a conformational change and releases heat-shock proteins (hsps). Phosphorylation (P) occurs before or after steroid binding. The AR translocates to the nucleus where dimerization, DNA binding, and the recruitment of coactivators occur. Target genes are transcribed (mRNA) and translated into proteins.[5][6][7][8]

The androgen receptor (AR), also known as NR3C4 (nuclear receptor subfamily 3, group C, member 4), is a type of

progestins in higher dosages can block the androgen receptor.[11][12]

The main function of the androgen receptor is as a

regulates gene expression;[13] however, the androgen receptor has other functions as well.[14] Androgen-regulated genes are critical for the development and maintenance of the male sexual phenotype
.

Function

Effect on development

In some cell types, testosterone interacts directly with androgen receptors, whereas, in others, testosterone is converted by

Wolffian duct, whereas dihydrotestosterone is the main androgenic hormone in the urogenital sinus, urogenital tubercle, and hair follicles.[16] Testosterone is therefore responsible primarily for the development of male primary sexual characteristics, whilst dihydrotestosterone is responsible for secondary male characteristics
.

Androgens cause slow maturation of the bones, but more of the potent maturation effect comes from the estrogen produced by aromatization of androgens. Steroid users of teen age may find that their growth had been stunted by androgen and/or estrogen excess. People with too little sex hormones can be short during puberty but end up taller as adults as in androgen insensitivity syndrome or estrogen insensitivity syndrome.[17]

neuroendocrine mechanisms.[18]

Maintenance of male skeletal integrity

Via the androgen receptor, androgens play a key role in the maintenance of male skeletal integrity. The regulation of this integrity by androgen receptor (AR) signaling can be attributed to both osteoblasts and osteocytes.[19]

Role in females

The AR plays a role in regulating female sexual, somatic, and behavioral functions. Experimental data using AR

trabecular
bone structure is a result of DNA-binding-dependent actions of the AR in females.

Moreover, the importance of understanding female androgen receptors lies in their role in several genetic disorders including androgen insensitivity syndrome (AIS). Complete (CAIS) and partial (PAIS) which are a result of mutations in the genes that code for AR. These mutations cause the inactivation of AR due to mutations conferring resistance to circulating testosterone, with more than 400 different AR mutations reported.[citation needed]

Mechanism of action

Genomic

The primary mechanism of action for androgen receptors is

gene transcription
.

Androgens (also called androgenic hormones), such as testosterone or dihydrotestosterone, are understood to exert their primary effects through binding to an androgen receptor in the cytosol. The receptor is translocated to the nucleus upon androgen binding and ultimately results in the transcriptional regulation of a number of genes via androgen responsive elements.[20] This androgen response mechanism is perhaps best known and characterized in the context of male sexual differentiation and puberty, but plays a role in a variety of tissue types and processes.[21][22] Upon binding to androgens, the androgen receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen-responsive genes.[23]

The binding of an androgen to the androgen receptor results in a

ribosomes to produce specific proteins. One of the known target genes of androgen receptor activation is the insulin-like growth factor 1 receptor (IGF-1R).[26]
Thus, changes in levels of specific proteins in cells is one way that androgen receptors control cell behavior.

One function of androgen receptor that is independent of direct binding to its target DNA sequence is facilitated by recruitment via other DNA-binding proteins. One example is serum response factor, a protein that activates several genes that cause muscle growth.[27]

Androgen receptor is modified by post-translational modification through acetylation,[28] which directly promotes AR-mediated transactivation, apoptosis[29] and contact-independent growth of prostate cancer cells.[30] AR acetylation is induced by androgens[31] and determines recruitment into chromatin.[32] The AR acetylation site is a key target of NAD-dependent and TSA-dependent histone deacetylases[33] and long non-coding RNA.[34]

Non-genomic

More recently, androgen receptors have been shown to have a second mode of action. As has been also found for other

steroid hormone receptors such as estrogen receptors, androgen receptors can have actions that are independent of their interactions with DNA.[14][35] Androgen receptors interact with certain signal transduction proteins in the cytoplasm. Androgen binding to cytoplasmic androgen receptors can cause rapid changes in cell function independent of changes in gene transcription, such as changes in ion transport
. Regulation of signal transduction pathways by cytoplasmic androgen receptors can indirectly lead to changes in gene transcription, for example, by leading to phosphorylation of other transcription factors.

Genetics

Gene

In humans, the androgen receptor is encoded by the AR gene located on the X chromosome at Xq11–12.[36][37]

Deficiencies

At least 165 disease-causing mutations in this gene have been discovered.

Kennedy's disease.[40][41] In addition, point mutations and trinucleotide repeat polymorphisms have been linked to a number of additional disorders.[42]

CAG repeats

The AR gene contains

CAG repeats that affect receptor function, where fewer repeats leads to increased receptor sensitivity to circulating androgens and more repeats leads to decreased receptor sensitivity. Studies have shown that racial variation in CAG repeats exists,[43][44] with African-Americans having fewer repeats than non-Hispanic white Americans.[43]
The racial trends in CAG repeats parallels the incidence and mortality of prostate cancer in these two groups.

Mutations

The enhancer and the gene encoding for these receptors contain recurrent mutations, such as structural rearrangements and copy number changes, acquired in the progression of metastatic castration-resistant prostate cancer (mCRPC) treatment with therapy targeting these receptors (abiraterone, enzalutamide), make the disease progression determined by the androgen receptor genotype.[45]

Structure

Structural domains of the two isoforms (AR-A and AR-B) of the human androgen receptor. Numbers above the bars refer to the amino acid residues that separate the domains starting from the N-terminus (left) to C-terminus (right). NTD = N-terminal domain, DBD = DNA-binding domain, LBD = ligand-binding domain, AF = activation function.

Isoforms

Two isoforms of the androgen receptor (A and B) have been identified:[46]

Domains

Like other nuclear receptors, the androgen receptor is modular in structure and is composed of the following functional

domains labeled A through F:[48]

Splice variants

AR-V7 is an androgen receptor

splice variant that can be detected in circulating tumor cells of metastatic prostate cancer patients[58][59] and is predictive of resistance to some drugs.[60]

Clinical significance

High expression in androgen receptor has been linked to aggression and sex drive by affecting the HPA and HPG axis[61]

Aberrant androgen receptor coregulator activity may contribute to the progression of prostate cancer.[62][45]

Ligands

Affinities[a][63]
Compound
RBATooltip Relative binding affinity[b]
Metribolone 100
Dihydrotestosterone 85
Cyproterone acetate 7.8
Bicalutamide 1.4
Nilutamide 0.9
Hydroxyflutamide 0.57
Flutamide <0.0057
Notes:
  1. ^ At androgen receptors; measured in human prostate tissue.
  2. ^ Relative to Metribolone, which is by definition 100%

Agonists

Mixed

Antagonists

As a drug target

The AR is an important therapeutic target in

N-terminal domain, DNA-binding domain) of the protein are still under development.[64]

Drug resistance

Alteration of ARs may lead to treatment resistance (castration resistance) in prostate cancer as there may be

ligand binding domain, amplifications of the gene coding for this receptor or in its enhancer, mostly, suggesting the presence of different subclones with different genotypes of these receptors.[45]

Interactions

Androgen receptor has been shown to

interact
with:

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000169083 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000046532 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. PMID 7671849
    .
  6. .
  7. .
  8. .
  9. .
  10. .
  11. .
  12. .
  13. .
  14. ^ .
  15. .
  16. .
  17. .
  18. .
  19. .
  20. .
  21. .
  22. .
  23. .
  24. .
  25. .
  26. .
  27. .
  28. .
  29. .
  30. .
  31. .
  32. .
  33. ^ .
  34. .
  35. .
  36. .
  37. .
  38. .
  39. .
  40. .
  41. .
  42. .
  43. ^ .
  44. .
  45. ^ .
  46. .
  47. .
  48. .
  49. .
  50. .
  51. .
  52. .
  53. .
  54. .
  55. ^ .
  56. .
  57. .
  58. .
  59. .
  60. ^ "Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-02-27.
  61. PMID 22414851
    .
  62. .
  63. .
  64. ^ .
  65. .
  66. .
  67. ^ .
  68. .
  69. .
  70. .
  71. ^ .
  72. ^ .
  73. .
  74. .
  75. .
  76. .
  77. .
  78. .
  79. .
  80. .
  81. .
  82. .
  83. .
  84. .
  85. .
  86. ^ .
  87. .
  88. ^ Reutens AT, Watanabe G, Albanese C, McPhaul MJ, Balk SP, Pestell RG (1998). "Cyclin D1 binds activating mutants of the androgen receptor". US Endocrine Society Meeting (P1–528).
  89. PMID 11328859
    .
  90. .
  91. .
  92. .
  93. .
  94. .
  95. .
  96. .
  97. .
  98. .
  99. .
  100. .
  101. .
  102. .
  103. .
  104. ^ .
  105. .
  106. .
  107. ^ .
  108. .
  109. .
  110. .
  111. .
  112. .
  113. ^ .
  114. ^ .
  115. .
  116. .
  117. ^ .
  118. .
  119. .
  120. .
  121. .
  122. .
  123. .
  124. .
  125. .
  126. .
  127. .
  128. .
  129. .
  130. .
  131. ^ .
  132. .
  133. .
  134. .
  135. ^ .
  136. .
  137. .
  138. .
  139. .
  140. .
  141. .
  142. .
  143. .
  144. .
  145. .
  146. .
  147. .
  148. .
  149. .
  150. .
  151. .
  152. .
  153. .
  154. .
  155. .
  156. .
  157. .
  158. .
  159. .
  160. .
  161. .
  162. .
  163. .
  164. .
  165. .
  166. .

External links